10,431 Abbott Laboratories $ABT Shares Purchased by Farther Finance Advisors LLC

Key Points

• Farther Finance Advisors increased its Abbott Laboratories stake by 14.1% in the third quarter, purchasing 10,431 additional shares for a total holding of 84,377 shares valued at approximately $8.34 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott reported quarterly earnings of $1.31 per share, exceeding estimates by $0.03, while revenue rose 13% year over year to $12.59 billion. The company guided for full-year 2026 earnings of $5.45–$5.60 per share.
• Abbott declared a quarterly dividend of $0.63 per share, equating to an annualized $2.52 payout and a 2.5% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $118.88.

Farther Finance Advisors LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 14.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,377 shares of the healthcare product maker's stock after acquiring an additional 10,431 shares during the period. Farther Finance Advisors LLC's holdings in Abbott Laboratories were worth $8,339,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABT. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Bank of America Corp DE purchased a new position in Abbott Laboratories in the 2nd quarter worth approximately $1,603,607,000. Legal & General Group Plc bought a new position in shares of Abbott Laboratories in the 2nd quarter worth $1,082,524,000. Flossbach Von Storch SE purchased a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $902,938,000. Finally, Jupiter Topco LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth $732,788,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $99.71 on Friday. The firm has a market cap of $172.53 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.83 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $134.50. The firm has a 50-day moving average of $106.25 and a 200-day moving average of $98.35. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is currently 81.55%.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Royal Bank Of Canada reissued an "outperform" rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Bank of America cut their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. TD Cowen restated a "buy" rating and issued a $135.00 target price on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Finally, Robert W. Baird assumed coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $118.88.

Abbott Laboratories Profile

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.